MIT spinout NeuroBionics is pioneering a minimally invasive technique to treat neurological conditions like depression and Parkinson’s disease. The startup aims to deliver bioelectric fibers, the width of human hair, through blood vessels in the brain, eliminating the need for traditional deep brain surgery. Funded with $5 million, the technology utilizes carbon nanotubes instead of metals, reducing toxicity and improving MRI compatibility. NeuroBionics plans to test its device in pigs before seeking FDA approval, with market entry projected around 2030. Investor Steve Jurvetson highlights the vast potential of this innovation.